Last reviewed · How we verify
NCT03933787: NPY
Neuropeptide Y and Sympathovagal Balance
EARLY_PHASE1 trial testing Saxagliptin 5mg in Physical Activity in 7 participants. Completed in 15 April 2019.
18 July 2018
Quick facts
| Lead sponsor | Eric Grouzmann |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 7 |
| Start date | 5 June 2018 |
| Primary completion | 18 July 2018 |
| Estimated completion | 15 April 2019 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Saxagliptin 5mg — full drug profile →
- Placebo oral capsule
- ergometric test in healthy volunteers
Conditions studied
- Physical Activity — all drugs for Physical Activity →
- Sympathetic Nervous System — all drugs for Sympathetic Nervous System →
- Secretion; Catecholamine — all drugs for Secretion; Catecholamine →
Sponsor
Eric Grouzmann
Who can join
Adults 24 to 30, male only, with Physical Activity or Sympathetic Nervous System. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and Y2 receptors. This double-blind placebo-controlled crossover study investigated the sympathovagal balance during three exercises on a cycloergometer in healthy volunteers treated with saxagliptin (DPP4 inhibitor).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03933787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Saxagliptin 5mg
Trials testing the same drug.
- NCT04170790 — Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers · NA · unknown
- NCT04521049 — Tubular Markers in Response to Saxagliptin Therapy · Phase 4 · completed
- NCT03660683 — Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus · Phase 4 · terminated
- NCT03714594 — Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2. · Phase 2 · completed
- NCT02104804 — Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Ch · Phase 3 · completed
Other recruiting trials for Physical Activity
Currently open trials in the same condition.
- NCT07466797 — The eHealth Integrated Maternal Physical Activity Programme in Prenatal Care Trial (E-IMPACT) · NA · recruiting
- NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
- NCT07290309 — Survivors Uniting for Remote Guided Exercise · NA · recruiting
- NCT07415460 — Evaluating the Impact of SKY Breath Meditation on Stress, Well-being, and Connection in College Students · NA · recruiting
- NCT07585409 — Physical Activity in Persons With Parkinson's Disease · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03933787 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eric Grouzmann
- Last refreshed: 1 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03933787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing